Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing.

The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that delivered weight loss success by taking a daily pill. Novo Nordisk released data Wednesday showing that patients taking its new medication,

Weight loss injections are essentially the opposite of pills in terms of pros and cons. They’re generally more effective and there are fewer restrictions around the timing of the dose than pills. They’re typically only taken once per week, which may be an easier schedule to stick to, especially for people who don’t take many medications regularly.

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.

The drug manufacturer has developed a pill that could bring about weight loss of as much as 13% in three months, according to results of a Phase 1 trial. The pill isn’t Ozempic—it’s called Amycretin—but like that drug it mimics the GLP-1 hormone, which suppresses people’s appetites. It also mimics amylin, which makes people feel full.

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.